Carfilzomib is superior to bortezomib in rMM
نویسندگان
چکیده
منابع مشابه
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
HIV protease inhibitors (HIV-PI) are oral drugs for HIV treatment. HIV-PI have antitumor activity via induction of ER-stress, inhibition of phospho-AKT (p-AKT) and the proteasome, suggesting antimyeloma activity. We characterize the effects of all approved HIV-PI on myeloma cells. HIV-PI were compared regarding cytotoxicity, proteasome activity, ER-stress induction and AKT phosphorylation using...
متن کاملNonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
PURPOSE Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. Carfilzomib, a tetrapeptide epoxyketone proteasome inhibitor, currently in clinical investigation in myeloma, is associated with low rates of PN. We sought to d...
متن کاملBortezomib and Carfilzomib: a Link to Clinical Adverse Nonproteasomal Targets of the Proteasome Inhibitors
Purpose: Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. Carfilzomib, a tetrapeptide epoxyketone proteasome inhibitor, currently in clinical investigation in myeloma, is associated with low rates of PN. We sought to ...
متن کاملReverse Shoulder Arthroplasty is Superior to Hemiarthroplasty for Cuff Tear Arthropathy with Preserved Motion
Background: It is unclear whether hemiarthroplasty (HA) or reverse shoulder arthroplasty (RS) are superior for patientswith cuff tear arthropathy (CTA) and preserved preoperative motion (elevation >90˚).Methods: This was a retrospective, single institution study. Patients who underwent RSA or HA for CTA were included ifthey had preserved preoperative motion with a minimum of 2...
متن کاملAnti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
Prognosis of childhood acute lymphoblastic leukemia (ALL) has been dramatically improved. However, prognosis of the cases refractory to primary therapy is still poor. Recent phase 2 study on the efficacy of combination chemotherapy with bortezomib (BTZ), a proteasome inhibitor, for refractory childhood ALL demonstrated favorable clinical outcomes. However, septic death was observed in over 10% ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Clinical Oncology
سال: 2016
ISSN: 1759-4774,1759-4782
DOI: 10.1038/nrclinonc.2016.136